Eukaryotic elongation factor 2 kinase (eEF2K), a stress-responsive regulator of translational elongation, has emerged as a pivotal therapeutic target in triple-negative breast cancer (TNBC) due to its critical role in sustaining cancer cell survival under nutrient stress. Here, EEF2K is linked to triple-negative breast carcinoma.